A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, Emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy

Clinical Cancer Research

Volumn 11, Issue 5, 2005, Pages 1890-1898

  Davis, Ian D ^a,c   Kiers, Lynette ^b   MacGregor, Lachlan ^b   Quinn, Michael ^d   Arezzo, Joseph ^e   Green, Michael ^b,c,f   Rosenthal, Mark ^b,c   Chia, Michael ^g   Michael, Michael ^c,h   Bartley, Peter ^b   Harrison, Leonie ⁱ   Daly, Michael ⁱ  

^a AUSTIN HEALTH   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c Cancer Trials Australia   (Australia)

^d ROYAL WOMEN'S HOSPITAL   (Australia)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f WESTERN HOSPITAL   (Australia)

^g Burnside Hospital   (Australia)

^h PETER MACCALLUM CANCER CENTRE   (Australia)

ⁱ Zenyth Therapeutics Limited Australia   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL; RECOMBINANT LEUKEMIA INHIBITORY FACTOR AM424; RECOMBINANT LEUKEMIA INHIBITORY FACTOR EMFILERMIN; RECOMBINANT LEUKEMIA INHIBITORY FACTOR RHULIF; UNCLASSIFIED DRUG;

ADULT; AGED; AMPLITUDE MODULATION; AREA UNDER THE CURVE; ARTICLE; CANCER GROWTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; ELECTROPHYSIOLOGY; ERYTHEMA; FEMALE; HOFFMANN REFLEX; HUMAN; INJECTION SITE REACTION; LATENT PERIOD; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; NERVE CONDUCTION; NEUROLOGY; NEUROPATHY; PATIENT COMPLIANCE; PERIPHERAL NERVE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; RIGOR; SENSITIVITY ANALYSIS; SOLID TUMOR; VALIDATION PROCESS; VIBRATION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERLEUKIN-6; LEUKEMIA INHIBITORY FACTOR; LIPASE; MALE; MIDDLE AGED; NEOPLASMS; NEURAL CONDUCTION; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; PLACEBOS; PROSPECTIVE STUDIES; PROTEINS;

EID: 20144387524     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1655     Document Type: Article

References (31)

1. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 1994;35:304-11.
2. Hilkens PH, ven den Bent MJ. Chemotherapy-induced peripheral neuropathy. J Peripher Nerv Syst 1997;2:350-61.
3. Pace A, Bove L, Aloe A, et al. Paclitaxel neurotoxicity: clinical and neurophysiological study of 23 patients. Ital J Neurol Sci 1997;18:73-9.
4. Cavaletti G, Bogliun G, Zincone A, et al. Neuro- and ototoxicity of high-dose carboplatin treatment in poor prognosis ovarian cancer patients. Anticancer Res 1998;18:3797-802.
5. van Gerven JM, Moll JW, van den Bent MJ, et al. Paclitaxel (Taxol) induces cumulative mild neurotoxicity. Eur J Cancer 1994;30A:1074-7.
6. Markman M. Management of toxicities associated with the administration of taxanes. Expert Opin Drug Saf 2003;2:141-6.
7. van der Hoop RG, van der Burg ME, ten Bokkel Huinink WW, van Houwelingen C, Neijt JP. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer 1990;66:1697-702.
8. Openshaw H, Beamon K, Synold TW, et al. Neurophysiological study of peripheral neuropathy after high-dose paclitaxel: lack of neuroprotective effect of amifostine. Clin Cancer Res 2004;10:461-7.
9. Gearing DP, Gough NM, King JA, et al. Molecular cloning and expression of cDNA encoding a murine myeloid leukaemia inhibitory factor (LIF). EMBO J 1987;6:3995-4002.
10. Hilton DJ. LIF: lots of interesting functions. Trends Biochem Sci 1992;17:72-6.
11. Thoenen H. The changing scene of neurotrophic factors. Trends Neurosci 1991;14:165-70.
12. Curtis R, Scherer SS, Somogyi R, et al. Retrograde axonal transport of LIF is increased by peripheral nerve injury: correlation with increased LIF expression in distal nerve. Neuron 1994;12:191-204.
13. Gunawardana DH, Basser RL, Davis ID, et al. A phase I study of recombinant human leukemia inhibitory factor in patients with advanced cancer. Clin Cancer Res 2003;9:2056-65.
14. Report and recommendations of the San Antonio conference on diabetic neuropathy. Ann Neurol 1988;24:99-104.
15. Proceedings of a consensus development conference on standardized measures in diabetic neuropathy. Summary and recommendations. Muscle Nerve 1992;15:1167-70.
16. Diabetic polyneuropathy in controlled clinical trials: consensus report of the Peripheral Nerve Society. Ann Neurol 1995;38:478-82.
17. Bril V, Ellison R, Ngo M, et al. Electrophysiological monitoring in clinical trials. Roche Neuropathy Study Group. Muscle Nerve 1998;21:1368-73.
18. Arezzo JC, Zotova E. Electrophysiologic measures of diabetic neuropathy: mechanism and meaning. Int Rev Neurobiol 2002;50:229-55.
19. Greene DA, Arezzo JC, Brown MB. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology 1999;53:580-91.
20. Dougherty PM, Cata JP, Cordella JV, Burton A, Weng HR. Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 2004;109:132-42.
21. Cavaletti G, Bogliun G, Marzorati L, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology 2003;61:1297-300.
22. Shy ME, Frohman EM, So YT, et al. Quantitative sensory testing: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003;60:898-904.
23. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.
24. Apfel SC. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? Int Rev Neurobiol 2002;50:393-413.
25. Kurek JB, Austin L, Cheema SS, Bartlett PF, Murphy M. Up-regulation of leukaemia inhibitory factor and interleukin-6 in transected sciatic nerve and muscle following denervation. Neuromuscul Disord 1996;6:105-14.
26. Ikeda K, Iwasaki Y, Shiojima T, Kinoshita M. Neuroprotective effect of various cytokines on developing spinal motoneurons following axotomy. J Neurol Sci 1996;135:109-13.
27. Cheema SS, Richards L, Murphy M, Bartlett PF. Leukemia inhibitory factor prevents the death of axotomised sensory neurons in the dorsal root ganglia of the neonatal rat. J Neurosci Res 1994;37:213-8.
28. Ikeda K, Iwasaki Y, Tagaya N, Shiojima T, Kinoshita M. Neuroprotective effect of cholinergic differentiation factor/leukemia inhibitory factor on wobbler murine motor neuron disease. Muscle Nerve 1995;18:1344-7.
29. Kilpatrick TJ, Phan S, Reardon K, Lopes EC, Cheema SS. Leukaemia inhibitory factor abrogates paclitaxel-induced axonal atrophy in the Wistar rat. Brain Res 2001;911:163-7.
30. Finkelstein DI, Bartlett PF, Horne MK, Cheema SS. Leukemia inhibitory factor is a myotrophic and neurotrophic agent that enhances the reinnervation of muscle in the rat. J Neurosci Res 1996;46:122-8.
31. Boyle FM, Beatson C, Monk R, Grant SL, Kurek JB. The experimental neuroprotectant leukaemia inhibitory factor (LIF) does not compromise antitumour activity of paclitaxel, cisplatin and carboplatin. Cancer Chemother Pharmacol 2001;48:429-34.